Quest Magazine

NIH ALS Lithium Trial Stops

The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced Sept. 23, 2009, that they will stop their study after an interim analysis showed the drug was not beneficial. MDA is not a funder of this study.

NIH ALS Lithium Trial Stops

The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced Sept. 23, 2009, that they will stop their study after an interim analysis showed the drug was not beneficial. MDA is not a funder of this study.

NIH Cuts Short ALS Lithium Trial; MDA’s Trial Continues for Now

The investigators on a study of lithium carbonate in amyotrophic lateral sclerosis (ALS), funded by the National Institutes of Health, the ALS Association and the ALS Society of Canada, announced Sept. 23, 2009, that they will stop their study after an interim analysis showed the drug was not beneficial. MDA is not a funder of this study.

First Human Stem Cell Trials for ALS to be Conducted at MDA/ALS Center in Atlanta

The first FDA-approved human stem cell trial to treat amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease will be conducted at the Muscular Dystrophy Association ALS Center at Emory University in Atlanta. 

The Food and Drug Administration has given Neuralstem, Inc., a Maryland biotherapeutics company, the go-ahead to conduct a Phase 1 trial to study the safety of Neuralstem’s cells and surgical procedures.

ALS Research: Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

ALS Research: Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

DMD, BMD Research: Utrophin from Obesity Drug?

An experimental drug being developed to treat obesity and high blood lipid (fat) levels also may have promise for the treatment of Duchenne (DMD) and Becker (BMD) muscular dystrophies, according to new, MDA-supported research from the University of Ottawa.

MDA grantee Bernard Jasmin and graduate student Pedro Miura coordinated and led the study team, which published results online Sept. 10, 2009, in Human Molecular Genetics.

ALS Risk Raisers

A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are significantly different in people with and without the disease and may contribute to its development.

Obesity Drug Increases Utrophin

An experimental drug being developed to treat obesity and high blood lipid (fat) levels also may have promise for the treatment of Duchenne (DMD) and Becker (BMD) muscular dystrophies, according to new, MDA-supported research from the University of Ottawa.

MDA grantee Bernard Jasmin and graduate student Pedro Miura coordinated and led the study team, which published results online Sept. 10, 2009, in Human Molecular Genetics.

DMD Research: Diagnostic Delays Common

A study that analyzed medical records from four U.S. states has found that the average time between symptom onset and diagnosis of Duchenne muscular dystrophy (DMD) is 2.5 years, an interval that hasn't changed in two decades.

This delay in identification postpones treatment that can slow the progression of the disease and results in lost opportunities for genetic counseling of parents.

Pages